Cholestyramine NDC 33342-319

NDC codes

FDA NDC Directory

Product NDC (as listed)33342-319Labeler and product segments. Claims need a package NDC.

Product NDC at billing width33342-0319Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
33342-319-70	33342031970	60 POUCH in 1 CARTON (33342-319-70) / 5.7 g in 1 POUCH (33342-319-01)Marketed from Nov 21, 2024
33342-319-72	33342031972	42 POUCH in 1 CARTON (33342-319-72) / 5.7 g in 1 POUCH (33342-319-01)Marketed from Nov 21, 2024
33342-319-83	33342031983	239.4 g in 1 JAR (33342-319-83)Marketed from Nov 21, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cholestyramine
Generic name (nonproprietary): cholestyramine
Active ingredients: Cholestyramine — 4 g/5.7g
Dosage form: Powder, For suspension
Route: Oral
Labeler: Macleods Pharmaceuticals Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209109
Marketing start: Nov 21, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Bile-acid Binding Activity (Mechanism)
Identifiers: Product ID 33342-319_c41529f1-16d2-4ca3-91eb-f809571f5ae3SPL ID c41529f1-16d2-4ca3-91eb-f809571f5ae3SPL set ID c41529f1-16d2-4ca3-91eb-f809571f5ae3RxCUI 1801279UNII 4B33BGI082
Pharmacologic class: Bile Acid Sequestrant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N433342031970 followed by a unit qualifier and the quantity

Package 33342-0319-70. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 30, 2025.

Indications (excerpt from the label)

INDICATIONS & USAGE 1) Cholestyramine for oral suspension USP, light is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for oral suspension USP, light may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular diseas…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)